GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cipher Pharmaceuticals CPH.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

13.75

+1.78%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Cipher Pharmaceuticals — daily TSX:CPH Delayed
Market value
C$346.8m
Last close × shares
Volume
28.7k
Shares, 9 Nov 2026
Price to earnings
8.6

About Cipher Pharmaceuticals

Its shares trade on Toronto Stock Exchange under the ticker CPH.TO. It has been listed since 25 February 2004. In the fiscal year to 31 December 2025, it reported revenue of $51.3m and net income of $27.8m. At that date it held total assets of $156.2m and shareholders' equity of $126.0m.

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm has a portfolio of commercial and late-stage products. The company operates in the specialty pharmaceuticals segment. The company acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. The company operates in Canada and the United States.

Figures and description from our data supplier, not checked against the company's own report.

More about Cipher Pharmaceuticals →

Latest on Cipher Pharmaceuticals

Our reporting

We have not reported on Cipher Pharmaceuticals yet.

Next results

5 Nov 2026

Due on 5 Nov 2026. Analysts expect earnings of 0.28 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Cipher Pharmaceuticals's ticker?

Cipher Pharmaceuticals trades as CPH.TO on Toronto Stock Exchange, under ISIN CA17253X1050.

What was Cipher Pharmaceuticals's last closing price?

13.75 on 9 Nov 2026. The figure is in CAD and is never converted.

When does Cipher Pharmaceuticals next report results?

Results are expected on 5 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.